Innate Pharma (IPHA) financial statements

· Market cap $152M

Innate Pharma reported revenue of 9M EUR in fiscal 2025, down 18.0% a year over 8 years.

Net income was -49M EUR and the operating margin -599.8%, against -90.8% in 2017.

Free cash flow was -53M EUR.

The diluted share count rose 65% over the period (dilution).

Revenue and free cash flow

Fiscal years, $ billions (EUR).

-0.1-0.100.10.1201720182019202020212022202320242025RevenueFree cash flow
Embed this chart

Free to use in articles and newsletters with the source line. Paste this HTML:

Income statement

Fiscal years, in EUR, from Innate Pharma's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Revenue44M EUR94M EUR85M EUR70M EUR25M EUR58M EUR62M EUR20M EUR9M EUR
Research and development67M EUR70M EUR63M EUR50M EUR47M EUR52M EUR56M EUR52M EUR44M EUR
Selling, general and admin17M EUR18M EUR21M EUR19M EUR26M EUR22M EUR18M EUR20M EUR19M EUR
Operating income-40M EUR5M EUR2M EUR1M EUR-48M EUR-57M EUR-13M EUR-52M EUR-54M EUR
Interest expense113,000 EUR102,000 EUR204,000 EUR341,000 EUR312,000 EUR288,000 EUR640,000 EUR566,000 EUR440,000 EUR
Pre-tax income-48M EUR3M EUR8M EUR-829,000 EUR-45M EUR-58M EUR-8M EUR-49M EUR-49M EUR
Income tax368,000 EUR-333,000 EUR0 EUR0 EUR0 EUR0 EUR0 EUR0 EUR0 EUR
Net income-48M EUR3M EUR-21M EUR-64M EUR-53M EUR-58M EUR-8M EUR-49M EUR-49M EUR
EPS (diluted)-0.89 EUR0.05 EUR-0.31 EUR-0.81 EUR-0.66 EUR-0.73 EUR-0.09 EUR-0.61 EUR-0.55 EUR
Diluted shares54M59M67M79M80M80M80M81M90M
Operating margin-90.8%5.5%1.8%1.5%-193.6%-99.6%-20.6%-256.3%-599.8%
Net margin-109.9%3.2%-24.3%-91.7%-213.8%-100.7%-12.3%-245.9%-546.1%

Balance sheet

Fiscal years, in EUR, from Innate Pharma's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Cash and short-term investments116M EUR168M EUR219M EUR152M EUR120M EUR101M EUR92M EUR81M EUR34M EUR
Receivables21M EUR152M EUR19M EUR22M EUR18M EUR38M EUR56M EUR5M EUR12M EUR
Total current assets138M EUR320M EUR238M EUR173M EUR138M EUR140M EUR148M EUR86M EUR47M EUR
Property, plant and equipment11M EUR11M EUR12M EUR12M EUR10M EUR9M EUR6M EUR5M EUR4M EUR
Total assets255M EUR451M EUR401M EUR307M EUR267M EUR199M EUR175M EUR111M EUR63M EUR
Total current liabilities74M EUR197M EUR122M EUR45M EUR80M EUR41M EUR40M EUR33M EUR37M EUR
Total liabilities156M EUR284M EUR184M EUR151M EUR160M EUR145M EUR123M EUR102M EUR84M EUR
Shareholders' equity99M EUR167M EUR217M EUR156M EUR107M EUR54M EUR52M EUR9M EUR-22M EUR
Net debt-99M EUR-152M EUR-203M EUR-137M EUR-104M EUR-84M EUR-71M EUR-66M EUR-28M EUR

Cash flow

Fiscal years, in EUR, from Innate Pharma's 10-K filings with the SEC.

Fiscal year201720182019202020212022202320242025
Operating cash flow-48M EUR-33M EUR35M EUR-52M EUR-58M EUR-19M EUR-33M EUR-7M EUR-53M EUR
Capital spending6M EUR1M EUR65M EUR11M EUR1M EUR1M EUR2M EUR391,000 EUR140,000 EUR
Free cash flow-54M EUR-34M EUR-30M EUR-63M EUR-60M EUR-20M EUR-35M EUR-7M EUR-53M EUR
Stock-based compensation10M EUR3M EUR4M EUR2M EUR3M EUR4M EUR4M EUR4M EUR3M EUR
Net borrowing538,000 EUR-1M EUR12M EUR-885,000 EUR27M EUR-2M EUR-2M EUR-9M EUR-9M EUR
Free cash flow margin-122.8%-36.1%-35.7%-90.4%-242.0%-35.2%-56.6%-36.2%-587.4%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IPHA.
Open IPHA in Investingly

Questions

What was Innate Pharma's revenue in 2025?

9M EUR in fiscal 2025, from its 10-K filing.

How much free cash flow does Innate Pharma generate?

-53M EUR in fiscal 2025 (operating cash flow minus capital spending).

From Innate Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.